- Asia
- Automobile
- Bangladesh
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Competition Law
- Constitutional Law
- Consumer Law
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Right Management
- Educational Conferences/ Seminar
- Fashion Law
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Legal Issues
- Licensing
- Media & Entertainment Law
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Patent Act
- Patent Commercialisation
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- TAX
- Technology
- Telecom Law
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
Section 3(D) of Indian Patent Act Strikes Again
27th July, 2015 - 5:24 am
Categories:
India
News & Updates
patent infringement
Patent Opposition
Patents
pharma
Section 3(D)
0 Comments
India revoked yet another drug patent granted to a German MNC, Boehringer Ingelheim, for its respiratory drug, Spiriva (crystalline tiotropium bromide monohydrate) at a time when the US is putting pressure on the Indian government for not providing adequate patent protection to multinational drug companies. In its decision, the patent office held that Boehringer failed … Continue reading Section 3(D) of Indian Patent Act Strikes Again
Read more »